August 2023 Top Biopharma Deal: Poseida license option deal with Astellas for P-MUC1C-ALLO1

By Chris Dokomajilar

Sep 5, 2023

Deal of the month, Partnership Deals

August 2023 Top Biopharma Deal Upfront

Poseida license option deal with Astellas for P-MUC1C-ALLO1

Highlighted Deal Financial Comps

- Date Announced:
- ,
  August 7, 2023
- Total Deal Value:
- ,
  $50
- Upfront Cash:
- ,
  $25M
- Upfront Equity:
- ,
  $25M
- Option Payments:
- ,
  n/a
- Total Milestones:
- ,
  n/a
- Royalties:
- ,
  n/a
- Cost & Profit Split:
- ,
  n/a

Deal Synopsis

- The Asset:
- ,
  Poseida’s P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy for multiple solid tumors
- Deal Structure:
- ,
  Option to License (Right of First Negotiation)
- Partnership Features:
- ,
  Collaborative Development, No Shared Cost
- Deal Details:
- ,
  - Poseida granted Astellas an option for exclusive, worldwide rights to develop and commercialize P-MUC1C-ALLO1.
  - P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy for the treatment of multiple solid tumors.
  - Astellas to invest a total of $50M in Poseida:
    - $25M for approximately 8.8% of Poseida’s outstanding common stock (8,333,333 shares at $3.00 per share).
    - $25M one-time payment for exclusive negotiation and first refusal rights to license P-MUC1C-ALLO1.
  - Deal includes potential for Astellas to further invest in licensing and commercialization of the therapy in the future.
- Last Month:
- ,
  
  Congrats to Poseida and Astellas for landing DealForma’s August 2023 Top Biopharma Deal. Last month’s Deal of the Month was Alnylam – Roche for zilebesiran. Read about it here.
  
  DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
  
  We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

DealForma Research

Autoimmune R&D Partnerships, M&A, Ventures, and IPOs by TA – Q2 to QTD Q4 2024 Review

December 5, 2024

MedTech, Device, Digital Health, Wearables – M&A, Ventures and IPOs in Q3 2024

December 4, 2024

Biopharma Therapeutics and Platforms IPO Activity – Q3 2024

November 21, 2024

All of this by stage, disease indication, modality, target…

+ 0 k

Licensing Deals

+ 0 k

M&A

+ 0 k

Other Deals

+ 0 k

Funding Rounds

+ 0 k

Company Profiles

+ 0 k

Drug Sales Figures